The estimated Net Worth of Mitchell S Levine is at least $1.43 Million dollars as of 15 March 2022. Mr. Levine owns over 25,000 units of Oncocyte stock worth over $269,948 and over the last 7 years he sold OCX stock worth over $0. In addition, he makes $1,157,940 as Chief Financial Officer at Oncocyte.
Mitchell has made over 5 trades of the Oncocyte stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of OCX stock worth $29,250 on 15 March 2022.
The largest trade he's ever made was buying 25,000 units of Oncocyte stock on 15 March 2022 worth over $29,250. On average, Mitchell trades about 5,667 units every 61 days since 2017. As of 15 March 2022 he still owns at least 87,080 units of Oncocyte stock.
You can see the complete history of Mr. Levine stock trades at the bottom of the page.
Mitchell Levine serves as Chief Financial Officer of the Company. In 2000, Mr. Levine founded Enable Capital Management. LLC, the general partner of Enable Growth Partners, L.P. which provided growth capital to private and publicly traded companies, catalyzing transformative corporate innovation, job growth, and economic expansion in technology, life sciences, consumer products, and energy. Prior to founding Enable, Mr. Levine was a founding member of The Shemano Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies. He has also worked at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.
As the Chief Financial Officer of Oncocyte, the total compensation of Mitchell Levine at Oncocyte is $1,157,940. There are 2 executives at Oncocyte getting paid more, with Ronald Andrews having the highest compensation of $2,102,210.
Mitchell's mailing address filed with the SEC is 15, Cushing, Irvine Spectrum, Irvine, Orange County, California, 92618, United States.
Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin..., and Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: